Skip to Main Content

Paper Details

TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.
J Clin Invest
135
2021
M1, M2 macrophage, PD-1, PD-L1, TYRO3, anti-, anti-PD-1, anti-programmed cell death protein 1, cancer, mouse, patient, patients, programmed death ligand 1, tumor, tumoral, tumors
Author NameAffiliation
Zhou JiangThe University of Texas MD Anderson Cancer Center
Jun YaoThe University of Texas MD Anderson Cancer Center
Gabriel N HortobagyiThe University of Texas MD Anderson Cancer Center
Liuqing YangThe University of Texas MD Anderson Cancer Center
Mien-Chie HungGraduate Institute of Biomedical Sciences, Research Center for Cancer Biology and Center for Molecular Medicine, China Medical University
Mien-Chie HungAsia University
Mien-Chie HungThe University of Texas MD Anderson Cancer Center
  • 1 - 7

Datasets

Release 1.2